icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
See also
Décision d'accès précoce
22/12/2022
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
XgWT2RWC7GcFvsYF